- Home
- ATEC vs DNTH Comparison
ATEC vs DNTH Comparison
Compare ATEC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEC | DNTH |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATEC | DNTH |
|---|---|---|
| Price | $13.90 | $50.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $22.36 | ★ $70.22 |
| AVG Volume (30 Days) | ★ 4.2M | 983.9K |
| Earning Date | 02-24-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $728,020,000.00 | $3,078,000.00 |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $16.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.11 | N/A |
| 52 Week Low | $8.81 | $13.37 |
| 52 Week High | $23.29 | $57.50 |
Technical Indicators
Market Signals| Indicator | ATEC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 26.75 | 54.21 |
| Support Level | $13.43 | $46.03 |
| Resistance Level | $15.55 | $54.85 |
| Average True Range (ATR) | 0.70 | 3.17 |
| MACD | -0.15 | -0.40 |
| Stochastic Oscillator | 6.91 | 41.82 |
Price Performance
Historical ComparisonAbout ATEC Alphatec Holdings Inc.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.